Related Experiment Video

Updated: Aug 9, 2026

Activating Autophagy by Aerobic Exercise in Mice
08:44

Activating Autophagy by Aerobic Exercise in Mice

Published on: February 3, 2017

12.3K

Identification and cross-validation of autophagy-related genes in cardioembolic stroke

Yufang Yang1, Min Zhang2, Ziqing Li1

  • 1School of Basic Medical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Frontiers in Neurology
|June 12, 2023
PubMed

Insights

Cardioembolic stroke (CE stroke) involves autophagy. Bioinformatics identified 41 autophagy-related genes, including SERPINA1 and CXCR4, offering potential therapeutic targets for CE stroke treatment.

Area of Science:

  • Biomedical research
  • Genomics
  • Molecular biology

Background:

  • Cardioembolic stroke (CE stroke) is a severe subtype of ischemic stroke with high recurrence and fatality rates.
  • The underlying pathogenesis of CE stroke is not fully understood, though autophagy is implicated.
  • Identifying molecular markers and therapeutic targets is crucial for improving CE stroke outcomes.

Purpose of the Study:

  • To identify potential autophagy-related molecular markers for CE stroke using bioinformatics.
  • To uncover potential therapeutic targets for CE stroke based on autophagy-related gene expression.
  • To elucidate the role of autophagy in the development of CE stroke.

Main Methods:

  • Utilized the GSE58294 mRNA expression dataset from the GEO database.
  • Screened for autophagy-related differentially expressed (DE) genes in CE stroke using R software.
  • Performed protein-protein interaction (PPI), correlation, and Gene Ontology (GO) enrichment analyses.
  • Verified DE genes using datasets GSE66724, GSE41177, and GSE22255 with Student's t-test.

Main Results:

  • Identified 41 autophagy-related DE genes (37 upregulated, 4 downregulated) between CE stroke patients and healthy controls.
  • GO and KEGG enrichment analyses revealed terms related to autophagy, apoptosis, and ER stress.
  • Discovered hub genes, including CXCR4 (general stroke) and specific CE stroke genes like ARNT, MAPK1, ATG12, ATG16L2, ATG2B, and BECN1.

Conclusions:

  • Identified 41 autophagy-related genes as potential biomarkers for CE stroke.
  • SERPINA1, WDFY3, ERN1, RHEB, and BCL2L1 are significant DE genes potentially regulating CE stroke via autophagy.
  • The findings provide insights into autophagy's role in CE stroke and suggest novel therapeutic targets.
Abstract

Keywords:
autophagybioinformatics analysiscardioembolic strokegene expression omnibus datasethub genes

More Related Videos

Assessing Autophagic Flux by Measuring LC3, p62, and LAMP1 Co-localization Using Multispectral Imaging Flow Cytometry11:39

Assessing Autophagic Flux by Measuring LC3, p62, and LAMP1 Co-localization Using Multispectral Imaging Flow Cytometry

Published on: July 21, 2017

31.4K
Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke11:32

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Published on: January 3, 2025

974

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...